Optison (FS069) disrupts the blood-brain barrier in rats

Anesthesia and Analgesia

Volumn 91, Issue 4, 2000, Pages 798-803

  Mychaskiw II, George ^a,b   Badr, Ahmed E ^a   Tibbs, Robert ^a   Clower, Ben R ^b   Zhang, John H ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; FLUORINE DERIVATIVE; FS 069; KETAMINE; PROPANE; XYLAZINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD PRESSURE; BRAIN CIRCULATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART; HISTOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0033799637     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-200010000-00007     Document Type: Article

References (14)

1. Echocardiography of the aortic root
2. Opacification and border delineation improvement in patients with suboptimal border definition in routine echocardiography: Results of the phase III Albunex multicenter trial
3. Intravenous contrast echocardiography with use of sonicated albumin in humans: Systolic disappearance of left ventricular contrast after transpulmonary transmission
4. Identifying the cause of left ventricular systolic dysfunction after coronary artery bypass surgery: The role of myocardial contrast echocardiography
5. Relation between air-filled albumin microbubble and red cell rheology in the human myocardium: Influence of echocardiographic systems and chest wall attenuation
6. Clinical applications of transpulmonary contrast echocardiography
7. Myocardial contrast echocardiography: Reliable, safe and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent
8. Physiologically based pharmacokinetic model for fluorocarbon elimination after the administration of an octafiuoropropane-albumin microsphere sonographic contrast agent
9. Improved left ventricular border delineation and opacification with Optison (FS069), a new echocardiographic contrast agent: Results of a phase III multicenter trial
10. Lack of bioeffects of ultrasound after intravenous administration of FS069 (Optison) in the anesthetized rabbit
11. Ultrasound-induced cell lysis and sonoporation enhanced by contrast agents
12. Subharmonic generation from ultrasonic contrast agents
13. Enhancement of ultrasonically-induced hemolysis by perfluorocarbon-based compared to air-based echo-contrast agents